HANSA BIOPHARMA

Investor Presentation

Gene Therapy opportunity
H.C. Andersen Capital event
Friday November 5, 2021

Lena Winstedt
Global Franchise Lead
Hansa Biopharma

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Hansa Biopharma today

Successful track record...
Strong momentum...
Promising future...

A validated technology

VALIDATION ACROSS THREE AREAS

- Approval in kidney transplantations
- PoC in autoimmune diseases
- Partnership to explore gene therapy

Idefirix® our first approved drug in Europe*

EUROPE KIDNEY TRANSPLANTS

For highly sensitized patients in Europe

Broad pipeline in transplantation and autoimmunity

PROGRAMS IN CLINICAL DEVELOPMENT

US Kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

Established a high-performance organization

NEW COMPETENCIES ADDED

130 employees (~3x in 3 years)

Highly qualified team with 20 years on average in life science

Purpose driven culture

With recent capital injection Hansa is financed into 2023

FINANCIALS

SEK ~1bn/USD ~115m in cash end of September 2021

Created shareholder value and diversified our ownership base

MCAP USD ~0.7bn

Listed on Nasdaq Stockholm

17,000 shareholders

Foreign ownership make up ~50% through leading international life science specialist funds

*Idefirix approved in EEA under conditional approval for kidney transplantation

*Actual patient has given consent to provide images

Our unique antibody cleaving enzyme technology may have relevance across a range of indications

targeting rare IgG mediated diseases

Anti-GBM paves the way for further development in autoimmune diseases

- Rapidly progressive glomerulonephritis (e.g. Lupus, ANCA-associated vasculitis)
- Neurological disorders (e.g. NMO, CIDP, Myasthenia gravis)
- Skin and blood disorders (e.g. EBA, WAHA ITP, APS etc)

Can IgG cleaving enzymes enable or even potentiate cancer therapy?

- Allogenic stem cell (bone marrow) transplantation
- Enzyme-based antibody Enhancement
- Cell therapy: Chimeric antigen receptor T cells (e.g. Allogenic CAR-T)

Next generation IgG cleaving enzymes - NICER



Shaping a new standard for desensitization will help enable new indications in transplantations

- Managing antibody mediated rejection episodes (AMR) in kidney transplantation
- Living donor kidney transplantation
- Lung transplantation (pre and post)
- Heart transplantation (pre and post)

Exploring opportunities in gene therapy

- Neutralizing antibodies (Nabs) are immunological barriers in gene; imlifidase may potentially eliminate Nabs
- Between approximately 5% and 70% of patients considered for gene therapy treatment carry Nabs forming a barrier for treatment eligibility
- Encouraging preclinical outcome highlighted in Nature

HANSA BIOPHARMA

Gene Therapy

HANSA BIOPHARMA



Exploring opportunities in gene therapy

Exploring the opportunities in systemic administration of gene therapy for our unique antibody cleaving enzyme platform to potentially enable gene therapy treatment in Nab+ patients

A revolutionary approach

Significant unmet need

Encouraging pre-clinical data

Partnership strategy

Stock images

Neutralizing antibodies (Nabs) are immunological barriers in gene therapy; imlifidase may potentially eliminate Nabs

Between approximately 5% and 70%[1,2] of patients considered for gene therapy treatment carry neutralizing anti-AAV antibodies forming a barrier for treatment eligibility

1 Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern

2 Imlifidase is a unique IgG antibody-cleaving enzyme that cleaves IgG at the hinge region with extremely high specificity

3 The idea is to eliminate the neutralizing antibodies as a pre-treatment to enable gene therapy



[1] Boutin (2010)
[2] Kruzik (2019)

HANSA BIOPHARMA

Tropism and target tissue

AAV subtypes targets different tissues

AAV 1, 2 & 5

Eye (local target)
~1x10^{11} vg



AAV 3, 7 & 8



Liver (systemic)
~1x10^{14} vg



Brain (local target)
~1x10^{12} vg



AAV 4 & 8



Muscle (systemic)
~1x10^{15} vg



AAV 6, 7, rh74

Target tissues
Dose of gene therapy (vg)

HANSA BIOPHARMA

Neutralizing antibodies are a barrier that precludes gene therapies

from working in a large group of patients. The prevalence of nabs varies significantly across the different vectors



Source: Boutin et al (2010), Griffin et al (2019), Wang et al (2018), Calcedo & Wilson (2013), Falese et al (2017), Haiyan et al (2017), Ellsworth et al (2018), Greig et al (2017)

HANSA BIOPHARMA

Imlifidase (IdeS) was highlighted in Nature Medicine[1]

with encouraging outcome demonstrating imlifidase as a potential solution to overcome pre-existing antibodies to AAV-based gene therapy


nature medicine

LETTERS

https://doi.org/10.1038/s41591-020-0911-7

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Christian Leborgne[1,5], Elena Barbon[1,5], Jeffrey M. Alexander[2,5], Hayley Hanby[2], Sandrine Delignat[3,4], Daniel M. Cohen[2], Fanny Collaud[1], Saghana Muraleetharan[2], Dan Lupo[2], Joseph Silverberg[2], Ren Huang[2], Laetitia van Wittenberghe[1], Béatrice Marolleau[1], Adeline Miranda[1], Anna Fabiano[1], Oria Daventure[3,4], Heena Beck[2], Xavier M. Anguela[2], Giuseppe Ronzitti[1,5], Sean M. Armour[2,5], Stien Lacroix-Desmazes[3,4] and Federico Mingozzi[1,2]

Imlifidase tested in a mouse model

- Imlifidase decreased anti-AAV antibodies and enabled efficient gene transfer



Imlifidase tested in NHP ahead of AAV vector infusion

- Pre-treatment with imlifidase in anti-AAV positive nonhuman primates (NHP) ahead of AAV vector infusion was safe and resulted in enhanced liver transduction and hFVIII plasma levels



Imlifidase tested in human plasma samples (GT patients)

- Imlifidase reduced anti-AAV antibody levels from human plasma samples in vitro, incl. plasma from prospective gene therapy trial participants



[1] Nature Medicine https://doi.org/10.1038/s41591-020-0911-7
Leborgne et al. Nat Med (2020)

HANSA BIOPHARMA

Exclusive agreement with Sarepta Therapeutics

to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications

A unique opportunity to combine efforts...

…and to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today aren't eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two indications with a very high unmet medical need

Structure of the partnership

Sarepta will be responsible for conducting

- Pre-clinical/clinical studies with imlifidase
- Regulatory approvals
- Promotion of imlifidase as a pre-treatment to Sarepta's gene therapies following potential approval

Hansa will supply product, support with know-how and involve in the regulatory approval process

Hansa's financial participation

Potential total deal value for Hansa amounts to up to USD ~400m plus royalties and incremental imlifidase sales

Hansa's key competences

- Leader in immunomodulatory enzyme technology for rare IgG mediated diseases
- Strong experience in antibody cleaving and desensitization
- Broad enzyme technology that can be used in a variety of indications

Sarepta's key competences

- Market leader within gene therapy targeted at muscular dystrophies
- Strong pre-clinical and clinical gene therapy portfolio
- Scientific approach and knowledge within gene therapy
- Experience with challenges of Nab-positive patients



Upfront payment
Hansa to receives a USD 10 million upfront payment from Sarepta for accessing Hansa's unique IgG antibody-cleaving enzyme technology (imlifidase)

Milestones
Hansa is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments.

Royalties & Sales
Hansa to receive high single-digit to mid-teens royalties on Sarepta's gene therapy sales enabled with imlifidase treatment in Nabs positive patients and book all sales of imlifidase

Systemic gene therapy is an emerging opportunity

with a focus on the potential to correct issues causing genes in rare monogenic diseases



Duchenne Muscular Dystrophy (DMD) SRP-9001

About Duchenne Muscular Dystrophy(DMD)[1]

- Rare, fatal neuromuscular genetic disease
- Muscle weakness noticeable by age 3 to 5, and most patients use a wheelchair by the time they are 11
- Cardiac and respiratory muscle deterioration becomes life-threatening
- 1/3,500 to 5,000 male births (worldwide)
- Approximately 15% of patients have pre-existing IgG antibodies to rh74

SRP-9001 micro-dystrophin gene therapy

- AAVrh74 vector with micro-dystrophin transgene
- Ongoing clinical studies show good efficacy and a favourable safety profile

Dystrophin expression in muscle tissue



Source:
[1] Sarepta Therapeutics https://investorrelations.sarepta.com/static-files/e9393c38-646f-45ee-9f56-955f3fbfad71
[2] National Institutes of Health. Genetics Home Reference. Duchenne and Becker muscular dystrophy. https://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy. Accessed Jan 2020.
[3] Sarepta Therapeutics https://investorrelations.sarepta.com/static-files/e9393c38-646f-45ee-9f56-955f3fbfad7

HANSA BIOPHARMA

Limb-Girdle muscular dystrophy (LGMD) SRP-9003

About limb-girdle muscular dystrophy

Limb-girdle muscular dystrophy is a group of diseases that cause weakness and wasting of the muscles

- May be caused by a single gene defect affecting specific proteins within muscle cells
- Approximate global prevalence of 1.63 per 100,000 individuals; over 30 subtypes exist
- Approximately 15% of patients have pre-existing IgG antibodies to rh74

SRP-9003 β-sarcoglycan gene therapy

- AAVrh74 vector with transgene β-sarcoglycan
- Open label study ongoing (n=6)
- Ongoing clinical studies show good efficacy and a favourable safety profile

β-sarcoglycan I muscle tissue



Source:
[1] Sarepta Therapeutics https://investorrelations.sarepta.com/static-files/e9393c38-646f-45ee-9f56-955f3fbfad71
[2] National Institutes of Health. Genetics Home Reference. Duchenne and Becker muscular dystrophy. https://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy. Accessed Jan 2020.
[3] Sarepta Therapeutics https://investorrelations.sarepta.com/static-files/e9393c38-646f-45ee-9f56-955f3fbfad7

HANSA BIOPHARMA


HANSA
BIOPHARMA

Corporate Contacts

Investor Relations and Corporate Communications

Visit our web site
www.hansabiopharma.com



Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Katja Margell

Head of Corporate Communications

Mobile: +46 (0) 768-198 326

Email: katja.margell@hansabiopharma.com

Calendar and events

Nov 5, 2021	HC. Andersen Capital – Gene Therapy opportunity (virtual)
Nov 10, 2021	Ökonomisk Ugebrev Life Science Conf., Copenhagen
Nov 11, 2021	Redeye Life Science Day 2021, Stockholm
Nov 18-19, 2021	Jefferies Global Healthcare Conference, London/virtual
Nov 25, 2021	Erik Penser Banks Bolagsdag, Stockholm/virtual
Dec 1-2, 2021	Geneva European MidCap event
Dec 16, 2021	DNB Nordic Healthcare Conference (virtual)
Jan 9-13, 2021	JPM Week, San Francisco
Jan 10-13, 2021	HC Wainwright BioConnect (virtual)
Feb 3, 2022	**Year-End report for Jan - Dec 2021**
Mar 15, 2021	Carnegie Healthcare Seminar 2022, Stockholm

HANSA BIOPHARMA